Author: Claude (AI), from PubMed abstracts · Reviewed by: Dr Mina Abdelmseih · Reviewed: 2026-11-15 · Review due: 2027-11-15

Educational content only. Not personalised medical advice. Clinical decisions remain the responsibility of the treating clinician.

Vogt-Koyanagi-Harada Disease

Vogt-Koyanagi-Harada (VKH) disease is a rare multisystem autoimmune disease directed against melanocytes, affecting the eye, inner ear, meninges and skin, with bilateral uveitis at its core [S2]. It is a primary stromal choroiditis that spills over into panuveitis [S4]. Early, vigorous and sustained treatment at initial onset can prevent chronic disease and sunset glow fundus, whereas delayed treatment risks chronic uveitis and permanent visual impairment [S6] [S12].

Key points - Treat initial-onset disease early and aggressively with systemic corticosteroids [S2] [S3]; expert reviews favour adding non-steroidal immunosuppression from the start [S6] [S7]. - Pooled observational data: chronic evolution in 44% after corticosteroids alone vs 2.3% with immediate dual therapy [S6]. - Chronic recurrent VKH is more refractory, has more complications and poorer outcomes than initial-onset acute disease [S5]. - OCT shows exudative retinal detachment and choroidal thickening in the acute stage and choroidal thinning in the chronic stage [S3]. - Atypical central serous chorioretinopathy (CSCR) can be misdiagnosed as VKH; giving steroids for CSCR can cause permanent visual loss [S1].

Evidence last checked: 2026-10-17 (PubMed abstracts).

Red flags

• Bilateral serous retinal detachments with disc oedema and vitritis [S3]: a pattern that needs prompt treatment to avoid complications [S3].
• Delay in diagnosis. Delayed diagnosis and treatment lead to chronic uveitis and permanent visual impairment [S12]; the "therapeutic window of opportunity" is emphasised [S6].
• Serous detachment that could be CSCR. Ask about corticosteroid use; misdiagnosis leads to inappropriate steroids and permanent visual loss [S1].
• Exclude infection. Diagnosis requires bilateral involvement and ruling out other conditions such as tuberculosis [S10].
• Cancer immunotherapy. PD-1 inhibitors can cause VKH-like uveitis [S12].

Recognise it

• Who. People with darker skin pigmentation, most often Asians, Native Americans and Hispanics; usually aged 20 to 50 years, female:male ratio 2:1 [S2]. HLA-DRB1*0405 is the main susceptibility allele [S2].
• Phases. Prodromal, uveitic, convalescent and recurrent [S3]. It often begins with vague viral-like systemic symptoms [S2].
• Eye. Severe bilateral granulomatous inflammation with serous retinal detachments, disc oedema and vitritis, later sunset glow fundus [S3].
• Outside the eye. Headache, meningismus, hearing loss, poliosis, vitiligo [S3] and alopecia [S2].
• Key mimic. Atypical CSCR can be misdiagnosed as an inflammatory serous detachment, mainly VKH [S1].

Confirm it

• OCT shows exudative detachments and choroidal thickening (acute) and choroidal thinning (chronic) [S3].
• ICGA and enhanced-depth OCT. Diffuse choroiditis on ICGA and/or EDI-OCT is proposed as the essential criterion for initial-onset disease and the method of choice for monitoring [S7]. Hypofluorescent dark dots, RPE undulations and flow voids are key imaging features [S11].
• Other modalities: colour photography, fluorescein angiography and B-scan ultrasonography also contribute; access to advanced modalities varies [S11].
• OCTA shows reduced retinal and choriocapillaris vessel density in active disease and may help follow-up [S9].

Manage it

Before acting on this section, check the national and local guidelines, product information and regulatory approvals that apply where you practise. See the medical disclaimer.

Tier A (primary care / no specialist)

• A patient with headache or viral-like illness followed by blurred vision in both eyes, or with hearing loss, poliosis or vitiligo and eye symptoms, needs eye assessment (timing in the table below) [S2] [S3].

Tier B (general eye clinic)

1. Confirm bilateral posterior involvement with OCT or B-scan, and exclude tuberculosis and other mimics [S10] [S11].
2. Start systemic corticosteroids early and aggressively [S2] [S3]. Steroid pulse therapy controls inflammation but carries risks of hypertension, infection and electrolyte imbalance [S10]. Doses are not covered by these abstracts: follow local protocols.
3. Add a non-steroidal immunosuppressant at onset where possible; chronic evolution fell from 61% with corticosteroid monotherapy to 2% with combined therapy in international series [S4].

Tier C (specialist centre)

1. Which immunosuppressant. In a Chinese RCT of 110 patients (75% late-phase), a cyclosporine-based strategy was non-inferior to an adalimumab-based strategy for vision at 26 weeks (11.2 vs 6.3 letters), with fewer serious adverse events (0.70 vs 1.21 per patient-year) [S8]. Both arms used a non-standard corticosteroid regimen [S8].
2. Monitor subclinical choroiditis with ICGA and EDI-OCT; most patients could stop treatment without relapse in several studies [S7].
3. Chronic recurrent disease needs prognosis-aware planning because it is more refractory [S5].
4. Complications. Sunset glow fundus, cataract, glaucoma, subretinal fibrosis and choroidal neovascularisation [S3]; intravitreal corticosteroid may be needed for ocular complications [S2].
5. Pregnancy. Needs a multidisciplinary approach; corticosteroids can cause infection, fetal growth restriction and possible neurodevelopmental effects [S10].

Refer when

Pitfalls

• Treating initial-onset VKH with a short or low-intensity steroid course alone [S4] [S6].
• Calling atypical CSCR "VKH" and giving steroids [S1].
• Assuming Japanese outcomes apply everywhere: chronic evolution after corticosteroids alone was less frequent in Japan (25%), though sunset glow fundus still reached 61% [S4].
• Stopping follow-up when the fundus looks quiet; subclinical choroidal inflammation needs monitoring [S7].

Evidence notes

• The case for immediate dual therapy rests on comparisons across observational studies, not RCTs, and the authors note it is still contested [S6]; several reviews share authors [S4] [S6] [S7].
• The only RCT compared two immunosuppressive strategies, mainly in late-phase disease [S8].
• Not covered by these sources: corticosteroid and immunosuppressant doses, taper duration, and outcomes in Africa.

Related articles

• Behçet Uveitis
• Biologics and Immunosuppression for Non-infectious Uveitis

References

See the numbered source list below. Each marker [S#] links to its PubMed and DOI record.